{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:13:36Z","timestamp":1764785616296,"version":"3.44.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40264-025-01543-8","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:32:37Z","timestamp":1744212757000},"page":"893-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Mortality in Users of Pimavanserin Compared with Other Atypical Antipsychotics in Patients with Parkinson\u2019s Disease Psychosis: An Update"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-6788","authenticated-orcid":false,"given":"Sapna","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-9431","authenticated-orcid":false,"given":"Lisa J.","family":"McQuay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-0358","authenticated-orcid":false,"given":"Joan","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0042-6599","authenticated-orcid":false,"given":"Rebecca","family":"MacKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3014-7508","authenticated-orcid":false,"given":"Heather E.","family":"Danysh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilesh","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5760-6965","authenticated-orcid":false,"given":"Mary S.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0994-5820","authenticated-orcid":false,"given":"J. Bradley","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"11","key":"1543_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/17512433.2017.1369405","volume":"10","author":"Y Kianirad","year":"2017","unstructured":"Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson\u2019s disease psychosis. Expert Rev Clin Pharmacol. 2017;10(11):1161\u20138. https:\/\/doi.org\/10.1080\/17512433.2017.1369405.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"1543_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996\u20131001. https:\/\/doi.org\/10.1001\/archneurol.2010.166.","journal-title":"Arch Neurol"},{"issue":"7","key":"1543_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1474-4422(18)30209-6","volume":"17","author":"The Lancet Neurology","year":"2018","unstructured":"The Lancet Neurology. Difficult choices in treating Parkinson\u2019s disease psychosis. Lancet Neurol. 2018;17(7):569. https:\/\/doi.org\/10.1016\/S1474-4422(18)30209-6.","journal-title":"Lancet Neurol"},{"key":"1543_CR4","unstructured":"Schleisman A, Spangler M, Knezevich E. Treatment of Parkinson\u2019s disease psychosis. 2016. https:\/\/www.uspharmacist.com\/article\/treatment-of-parkinsons-disease-psychosis."},{"issue":"1","key":"1543_CR5","doi-asserted-by":"publisher","first-page":"4938154","DOI":"10.1155\/2016\/4938154","volume":"2016","author":"N Divac","year":"2016","unstructured":"Divac N, Stojanovi\u0107 R, Savi\u0107 Vujovi\u0107 K, Medi\u0107 B, Damjanovi\u0107 A, Prostran M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson\u2019s disease. Behav Neurol. 2016;2016(1):4938154. https:\/\/doi.org\/10.1155\/2016\/4938154.","journal-title":"Behav Neurol"},{"issue":"9916","key":"1543_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)62106-6.","journal-title":"Lancet"},{"key":"1543_CR7","unstructured":"Pimavanserin prescribing information. Acadia Pharmaceuticals Inc. NUPLAZID\u2122 (pimavanserin) tablets, for oral use. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207318lbl.pdf. Accessed 12 Apr 2024."},{"issue":"1","key":"1543_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","volume":"170","author":"ER Dorsey","year":"2010","unstructured":"Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96\u2013103. https:\/\/doi.org\/10.1001\/archinternmed.2009.456.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1543_CR9","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/gerona\/glz045","volume":"74","author":"RE Kheirbek","year":"2019","unstructured":"Kheirbek RE, Fokar A, Little JT, Balish M, Shara NM, Boustani MA, et al. Association between antipsychotics and all-cause mortality among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2019;74(12):1916\u201321. https:\/\/doi.org\/10.1093\/gerona\/glz045.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1543_CR10","unstructured":"FDA. US Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. http:\/\/web.archive.org\/web\/20160906021649\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm053171.htm. Accessed 09 Aug 2024."},{"key":"1543_CR11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21090876","author":"AD Mosholder","year":"2022","unstructured":"Mosholder AD, Ma Y, Akhtar S, Podskalny GD, Feng Y, Lyu H, et al. Mortality among Parkinson\u2019s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries. Am J Psychiatry. 2022. https:\/\/doi.org\/10.1176\/appi.ajp.21090876.","journal-title":"Am J Psychiatry"},{"issue":"13","key":"1543_CR12","doi-asserted-by":"publisher","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","volume":"97","author":"YJ Hwang","year":"2021","unstructured":"Hwang YJ, Alexander GC, An H, Moore TJ, Mehta HB. Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease. Neurology. 2021;97(13):e1266\u201375. https:\/\/doi.org\/10.1212\/WNL.0000000000012601.","journal-title":"Neurology"},{"issue":"2","key":"1543_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40264-022-01260-6","volume":"46","author":"JB Layton","year":"2023","unstructured":"Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, et al. Mortality in patients with Parkinson\u2019s disease\u2013related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023;46(2):195\u2013208. https:\/\/doi.org\/10.1007\/s40264-022-01260-6.","journal-title":"Drug Saf"},{"issue":"9","key":"1543_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161689","volume":"11","author":"L Kalilani","year":"2016","unstructured":"Kalilani L, Asgharnejad M, Palokangas T, Durgin T. Comparing the incidence of falls\/fractures in Parkinson\u2019s disease patients in the US population. PLoS ONE. 2016;11(9):e0161689. https:\/\/doi.org\/10.1371\/journal.pone.0161689.","journal-title":"PLoS ONE"},{"issue":"25","key":"1543_CR15","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"key":"1543_CR16","unstructured":"Parsons L. Performing a 1:N case-control match on propensity score. Presented at SUGI 29 Proceedings: SAS Users Group International Conference; 2004. Montreal, Canada. https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/sugi29\/165-29.pdf. Accessed 12 Apr 2024."},{"issue":"6","key":"1543_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.6004","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057\u201369. https:\/\/doi.org\/10.1002\/sim.6004.","journal-title":"Stat Med"},{"issue":"2","key":"1543_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361. https:\/\/doi.org\/10.1002\/pst.433.","journal-title":"Pharm Stat"},{"key":"1543_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/acprof:oso\/9780195124408.001.0001","volume-title":"Multivariate methods in epidemiology","author":"TR Holford","year":"2002","unstructured":"Holford TR. Proportional hazards regression. In: Multivariate methods in epidemiology. New York: Oxford University Press; 2002. p. 239\u201340."},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/acprof:oso\/9780195152968.003.0015","volume-title":"Applied longitudinal data analysis: modeling change and event occurrence","author":"JD Singer","year":"2003","unstructured":"Singer JD, Willett JB. Extending the Cox regression model. In: Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press, Inc; 2003. p. 543\u201379."},{"issue":"1","key":"1543_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/ADR-170042","volume":"2","author":"SJ Ralph","year":"2018","unstructured":"Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep. 2018;2(1):1\u201326. https:\/\/doi.org\/10.3233\/ADR-170042.","journal-title":"J Alzheimers Dis Rep."},{"issue":"8","key":"1543_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/aje\/kwy049","volume":"187","author":"SV Wang","year":"2018","unstructured":"Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, et al. Relative performance of propensity score matching strategies for subgroup analyses. Am J Epidemiol. 2018;187(8):1799\u2013807. https:\/\/doi.org\/10.1093\/aje\/kwy049.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"1543_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/070674371506000805","volume":"60","author":"P Kurdyak","year":"2015","unstructured":"Kurdyak P, Lin E, Green D, Vigod S. Validation of a population-based algorithm to detect chronic psychotic illness. Can J Psychiatry. 2015;60(8):362\u20138. https:\/\/doi.org\/10.1177\/070674371506000805.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"1543_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5334\/egems.281","volume":"7","author":"CC Stewart","year":"2019","unstructured":"Stewart CC, Lu CY, Yoon TK, Coleman KJ, Crawford PM, Lakoma MD, et al. Impact of ICD-10-CM transition on mental health diagnoses recording. EGEMS (Wash DC). 2019;7(1):14. https:\/\/doi.org\/10.5334\/egems.281.","journal-title":"EGEMS (Wash DC)."},{"issue":"3","key":"1543_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jagp.2021.07.018","volume":"30","author":"AG Hamedani","year":"2022","unstructured":"Hamedani AG, Weintraub D, Willis AW. Medicare claims data underestimate hallucinations in older adults with dementia. Am J Geriatr Psychiatry. 2022;30(3):352\u20139. https:\/\/doi.org\/10.1016\/j.jagp.2021.07.018.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"1543_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jamda.2017.09.021","volume":"19","author":"S Li","year":"2018","unstructured":"Li S, Middleton A, Ottenbacher KJ, Goodwin JS. Trajectories over the first year of long-term care nursing home residence. J Am Med Direct Assoc. 2018;19(4):333\u201341. https:\/\/doi.org\/10.1016\/j.jamda.2017.09.021.","journal-title":"J Am Med Direct Assoc."},{"issue":"16","key":"1543_CR27","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1080\/00036846.2021.1983138","volume":"54","author":"RJ Brent","year":"2022","unstructured":"Brent RJ. Life expectancy in nursing homes. Appl Econ. 2022;54(16):1877\u201388. https:\/\/doi.org\/10.1080\/00036846.2021.1983138.","journal-title":"Appl Econ"},{"issue":"11","key":"1543_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","volume":"146","author":"SS Gill","year":"2007","unstructured":"Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775\u201386. https:\/\/doi.org\/10.7326\/0003-4819-146-11-200706050-00006.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1543_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jama.2022.21795","volume":"329","author":"A Bilinski","year":"2023","unstructured":"Bilinski A, Thompson K, Emanuel E. COVID-19 and excess all-cause mortality in the US and 20 comparison countries, June 2021-March 2022. JAMA. 2023;329(1):92\u20134. https:\/\/doi.org\/10.1001\/jama.2022.21795.","journal-title":"JAMA"},{"issue":"25","key":"1543_CR30","doi-asserted-by":"publisher","first-page":"eadf9742","DOI":"10.1126\/sciadv.adf9742","volume":"9","author":"E Paglino","year":"2023","unstructured":"Paglino E, Lundberg DJ, Zhou Z, Wasserman JA, Raquib R, Luck AN, et al. Monthly excess mortality across counties in the United States during the COVID-19 pandemic, March 2020 to February 2022. Sci Adv. 2023;9(25):eadf9742. https:\/\/doi.org\/10.1126\/sciadv.adf9742.","journal-title":"Sci Adv"},{"issue":"10","key":"1543_CR31","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.jamda.2022.07.023","volume":"23","author":"CL Hua","year":"2022","unstructured":"Hua CL, Cornell PY, Zimmerman S, Carder P, Thomas KS. Excess mortality among assisted living residents with dementia during the COVID-19 pandemic. J Am Med Dir Assoc. 2022;23(10):1743\u20139. https:\/\/doi.org\/10.1016\/j.jamda.2022.07.023.","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"1543_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","volume":"21","author":"MA Hernan","year":"2010","unstructured":"Hernan MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13\u20135. https:\/\/doi.org\/10.1097\/EDE.0b013e3181c1ea43.","journal-title":"Epidemiology"},{"issue":"1","key":"1543_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1192\/bjp.bp.112.122499","volume":"205","author":"T Gerhard","year":"2014","unstructured":"Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014;205(1):44\u201351. https:\/\/doi.org\/10.1192\/bjp.bp.112.122499.","journal-title":"Br J Psychiatry"},{"issue":"9","key":"1543_CR34","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/aje\/kwr213","volume":"174","author":"KF Huybrechts","year":"2011","unstructured":"Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, et al. Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. Am J Epidemiol. 2011;174(9):1089\u201399. https:\/\/doi.org\/10.1093\/aje\/kwr213.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1543_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40801-021-00284-1","volume":"9","author":"JB Layton","year":"2022","unstructured":"Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, et al. Falls and fractures in patients with Parkinson\u2019s disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022;9(1):9\u201322. https:\/\/doi.org\/10.1007\/s40801-021-00284-1.","journal-title":"Drugs Real World Outcomes."},{"issue":"14","key":"1543_CR36","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","volume":"323","author":"MJ Stensrud","year":"2020","unstructured":"Stensrud MJ, Hernan MA. Why test for proportional hazards? JAMA. 2020;323(14):1401\u20132. https:\/\/doi.org\/10.1001\/jama.2020.1267.","journal-title":"JAMA"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01543-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:40:12Z","timestamp":1757155212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01543-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01543-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"11 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted by researchers at RTI Health Solutions, an independent nonprofit research organization. Funding for the research was received from Acadia Pharmaceuticals Inc., the manufacturer of pimavanserin. The contract between RTI Health Solutions and Acadia Pharmaceuticals Inc. includes independent publication rights.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"V.A. and D.D. are employees of Acadia Pharmaceuticals Inc., the manufacturer of pimavanserin. S.R., L.J.M., J.F., H.E.D., R.M., M.S.A., and J.B.L. are employed by RTI Health Solutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed using US Medicare data accessed through Medicare Research Identifiable Files, which were available for use upon approval and licensing under a data use agreement between the US Centers for Medicare and Medicaid Services (CMS) and RTI Health Solutions. The authors are not authorized to release data based on CMS privacy policies. However, data are available with permission from CMS () upon the establishment of a data use agreement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This analysis was determined to be exempt from full institutional review board review by the RTI International (RTI) institutional review board on 14 December 2020 (RTI IRB Study ID 00021361). The US CMS Privacy Board approved the use of Medicare Research Identifiable Files for this study under a data use agreement with RTI Health Solutions.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The RTI IRB determined that individual-level consent was not required for this analysis of secondary, deidentified data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"S.R., J.B.L., and J.F. contributed to the conceptualization, investigation, methodology, visualization, and writing of the original draft. H.E.D. and R.M. contributed to the resources, project administration, investigation, and writing for the review and editing drafts of the manuscript. L.J.M. contributed to the methodology, software, formal analysis, data curation, and writing for the review and editing drafts of the manuscript. D.D. and V.A. contributed to the investigation and writing for the review and editing drafts. M.S.A. contributed to the conceptualization, supervision, investigation, methodology, funding acquisition, and writing of the review and editing drafts. All authors have read and approve the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}